Evidence map›Paper›PMID 31935026›Full record

Trial reportJAMA2020

Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.

J Kellogg Parsons, David Zahrieh, James L Mohler, Electra Paskett, Donna E Hansel, Adam S Kibel, Heshan Liu, Drew K Seisler, Loki Natarajan, Martha White and 10 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01238172 (The Men's Eating and Living), which is not on this map. Cited by 39 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01238172 phase3completednot on this map

The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance

TypeinterventionalSponsorAlliance for Clinical Trials in OncologyRan2011 to 2019Enrolled478ConditionsProstate CancerArmsdietary education and counseling, prostate cancer foundation booklet
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

J Kellogg ParsonsDepartment of Urology, UC San Diego Moores Comprehensive Cancer Center and VA San Diego Healthcare System, La Jolla, California.
David ZahriehAlliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
James L MohlerDepartment of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Electra PaskettComprehensive Cancer Center, Department of Medicine, The Ohio State University College of Medicine, Columbus.
Donna E HanselDepartment of Pathology, University of California, San Diego, La Jolla.
Adam S KibelDivision of Urology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.
Heshan LiuAlliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
Drew K SeislerAlliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
Loki NatarajanDivision of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health and UC San Diego Moores Comprehensive Cancer Center, La Jolla, California.
Martha WhiteDivision of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health and UC San Diego Moores Comprehensive Cancer Center, La Jolla, California.
Olwen HahnAlliance Central Protocol Operations, University of Chicago, Chicago, Illinois.
John TaylorAlliance Central Protocol Operations, University of Chicago, Chicago, Illinois.
Sheri J HartmanMoores Cancer Center, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla.
Sean P StroupDepartment of Urology, Naval Medical Center San Diego, San Diego, California.
Peter Van VeldhuizenMenorah Medical Center, Midwest Oncology Associates, Overland Park, Kansas.
Lannis HallSiteman Cancer Center, Department of Radiation Oncology, Washington University, St Peters, Missouri.
Eric J SmallUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Michael J MorrisMemorial Sloan Kettering Cancer Center, New York, New York.
John P PierceMoores Cancer Center, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla.
James MarshallDepartment of Prevention and Population Sciences, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
RESEARCH BASE SUPPORT FOR COMMUNITY CLINICAL ONCOLOGY PRU10CA037447 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M, PASKETT, ELECTRA D. · 1985 to 2015
$25.3M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
Cancer and Leukemia Group B - The Ohio State UniversityU10CA077658 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 1998 to 2013
$6.0M
CANCER AND LEUKEMIA GROUP B--RPCI/SUNYABU10CA059518 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI LEVINE, ELLIS G · 1993 to 2013
$4.0M
CANCER AND LEUKEMIA GROUP B GRANT REVISED APPLICATIONU10CA041287 · NCI · UNIVERSITY OF CHICAGO · PI KINDLER, HEDY L · 1986 to 2013
$3.9M
MEMORIAL HOSPITAL AND CANCER AND ACUTE LEUKEMIA GROUP BU10CA077651 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI HUDIS, CLIFFORD A · 1998 to 2013
$3.2M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA132951NCI NIH HHS U10 CA037447NCI NIH HHS U10 CA041287NCI NIH HHS U10 CA059518NCI NIH HHS U10 CA077651NCI NIH HHS U10 CA077658NCI NIH HHS U10 CA138561NCI NIH HHS U10 CA180830NCI NIH HHS U10 CA180866NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189823NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233191
6 · The paper itself

Abstract

Importance: Guidelines endorsing vegetable-enriched diets to improve outcomes for prostate cancer survivors are based on expert opinion, preclinical studies, and observational data. Objective: To determine the effect of a behavioral intervention that increased vegetable intake on cancer progression in men with early-stage prostate cancer. Design, Setting, and Participants: The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) was a randomized clinical trial conducted at 91 US urology and medical oncology clinics that enrolled 478 men aged 50 to 80 years with biopsy-proven prostate adenocarcinoma (International Society of Urological Pathology grade group = 1 in those <70 years and ≤2 in those ≥70 years), stage cT2a or less, and serum prostate-specific antigen (PSA) level less than 10 ng/mL. Enrollment occurred from January 2011 to August 2015; 24-month follow-up occurred from January 2013 to August 2017. Interventions: Patients were randomized to a counseling behavioral intervention by telephone promoting consumption of 7 or more daily vegetable servings (MEAL intervention; n = 237) or a control group, which received written information about diet and prostate cancer (n = 241). Main Outcomes and Measures: The primary outcome was time to progression; progression was defined as PSA level of 10 ng/mL or greater, PSA doubling time of less than 3 years, or upgrading (defined as increase in tumor volume or grade) on follow-up prostate biopsy. Results: Among 478 patients randomized (mean [SD] age, 64 [7] years; mean [SD] PSA level, 4.9 [2.1] ng/mL), 443 eligible patients (93%) were included in the primary analysis. There were 245 progression events (intervention: 124; control: 121). There were no significant differences in time to progression (unadjusted hazards ratio, 0.96 [95% CI, 0.75 to 1.24]; adjusted hazard ratio, 0.97 [95% CI, 0.76 to 1.25]). The 24-month Kaplan-Meier progression-free percentages were 43.5% [95% CI, 36.5% to 50.6%] and 41.4% [95% CI, 34.3% to 48.7%] for the intervention and control groups, respectively (difference, 2.1% [95% CI, -8.1% to 12.2%]). Conclusions and Relevance: Among men with early-stage prostate cancer managed with active surveillance, a behavioral intervention that increased vegetable consumption did not significantly reduce the risk of prostate cancer progression. The findings do not support use of this intervention to decrease prostate cancer progression in this population, although the study may have been underpowered to identify a clinically important difference. Trial Registration: ClinicalTrials.gov Identifier: NCT01238172.

Indexed as

CounselingVegetablesWatchful WaitingAgedAged, 80 and overDisease ProgressionHumansMaleMiddle AgedNeoplasm StagingProstate-Specific AntigenProstatic NeoplasmsTelephoneProstate-Specific Antigen

Identifiers

PMID31935026
PMCPMC6990696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.